CCND1 expression, which did not significantly differ in untreated melanoma cells grown in the presence of different growth factors (Fig 1b) and was significantly reduced by 10 μM vemurafenib and 50 nM trametinib in cells grown in SCM containing bFGF and EGF [17], was more substantially reduced by trametinib when bFGF was not present in the medium, whereas treatment with vemurafenib induced further reduction of CCND1 expression only in the medium containing HGF (Fig 3a). Here, CCND1 is linked to melanoma.